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The occurrence range of proper lesions (neurofibrillary tangles and senile 
plaques) to Alzheimer’s disease: patho-anatomical study of a familial Alzheimer 
patient with the onset at age 38 and a 25-year clinical course
Noriaki Yoshimura１）
Abstract
AD is a rapidly increasing dementia whose measure for medical and social welfare has been a serious 
social problem in Japan.  The brain lesions of AD are characterized by 3 main histological changes: 
NFT, SP, and loss of neurons.  With the reexamination of an AD case with a 25 year-clinical course as 
an opportunity, the author revealed the maximal range of occurrence of NFT and SP in AD.  The results 
showed that neurons were classi›ed into 3 types: neuron types with NFT-rich, NFT-rare, and NFT-free. 
As to the pathogenesis of AD brain lesions, it is known that Aβ deposition occurs first and the 
oligomers with the highest toxicity develop into proto›brils and ›brils and ›nally form neuritic plaques 
which contain degenerated neurites. In addition, Aβ oligomers generated in and around synapses and 
inside neurons are considered to induce cell death due to the toxicity to neurons and glial cells. On the 
other hand, it is believed that by GSK3β which is activated by the overproduction of Aβ inside 
neurons, hyperphosphorylation of tau proceeds and soluble oligomers of tau polymerize to be insoluble 
granular aggregates, and then become larger insoluble NFT.  It is still unclear where tau oligomers or 
granules associate with Aβ oligomers or proto›brils to develop NFT and Aβ ›brils, respectively, and 
what mechanisms play roles to develop NFT in “NFT only tauopathies”.  Detailed analyses that 
reveal all of differences between NFT-rich and NFT-free neurons may open a road to pathogenetic 
mechanisms of  NFT formation.
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Introduction
Today, the population of people aged 65 and over in 
Japan is 25,560,000.  It is predicted that it will be over 
32,270,000 in 2015 and 34,730,000 in 2025, respectively
（The Ministry of Internal Affairs and Communications of 
Japan, 2005）.  Approximately 8% of these are estimated 
to be of the aged with dementia. Forty per cent of the 
aged with dementia will be patients with Alzheimerʼs 
disease（AD）and 30% with cerebrovascular dementia. 
The remaining 30% will consist of patients with other 
types of dementia which include dementia with Lewy 
bodies（DLB）, frontotemporal dementia（FTD）and so 
on. The aged with dementia who have shortages of 
pension and welfare funds have been increasing and 
are becoming a serious social problem in Japan.
The number of patients with cerebrovascular dementia 
has been decreasing by taking measures to lifestyle-
related diseases, whereas patients with AD have rapidly 
been increasing because there is no radical treatment 
for the disease so far.
  To find radical treatments it is necessary to know 
mechanisms of the disease in detail. Patients with AD 
clinically present a steady decline in cognitive ability 
beginning with the loss of short-term memory and 
progressing through stages of increasing dementia. 
The severity of the symptoms varies dramatically 
among individuals and the time of progression through 
these stages may take from months to years（Shoji et al., 
2005）.  These symptoms are related with histopathology 
of AD, whose hallmarks are intracellular neuroﬁbrillary 
tangles（NFT）composed of paired helical filaments
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Fig.1 A.  Right lateral view of the brain showing striking atrophy of individual gyri, accentuated in the frontal, temporal and 
parietal lobes. 
B.  Serial coronal sections of the right hemisphere of the brain showing marked atrophy of all gyri, basal ganglia, 
centrum semiovale, and hippocampus, and revealing marked dilatation of the lateral ventricle and Sylvian ﬁssure. 
BA
Fig.2 A.  Parahippocampal cortex showing several neuroﬁbrillary tangles (arrowheads), some of which are so-called ghost 
tangles (arrows).  Bodian stain  x    520
B.  Frontal cortex showing surviving neurons bare tangles and neuropil threads. Gallyas stain  x    260
C.  Parietal cortex showing that many of surviving neurons have NFT. Tau-immunostain x　260 
Tau-immunostainBodian stain
Gallyas stain
A C
B
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（PHF）of microtubule-associated protein, tau, and 
extracellular amyloid plaques（senile plaques; SP）, 
composed principally of the amyloid β peptide（Aβ）. 
For years, the amyloid cascade hypothesis proposed a 
central role for Aβ amyloid in the pathogenesis of AD
（Hardy& Higgins, 1992; Hardy & Selkoe, 2002）. 
However, the link between Aβ generation and NFT 
formation is not known yet（Lowe et al., 2008）.
  Recently, we reexamined an autopsied Alzheimer 
patient with the onset at age 38 and a 25-year clinical 
course.  Since the clinical course is very long, it is important 
to know which nuclei（neurons）are affected by the 
lesions peculiar to AD and which are not, when we 
consider the pathogenesis of NFT and/or SP.  The 
purpose of the present study is to clarify the occurrence 
range of NFT（and SP）, in order to obtain some clue to 
the pathogenesis of NFT.
Subjects and Methods 
The patient was a 65-year-old house-wife when she 
died. At the age of 38, she initially developed 
progressive dementia. From the age of 46, myoclonic 
jerks which occasionally developed into general 
convulsions, polyphagia, dysphagia and aspiration 
pneumonia appeared subsequently. The patient became 
bed-ridden with contractured extremities. The gene 
analysis performed with her familyʼs consent revealed a 
point mutation in the presenilin-1 gene（Tanahashi et 
al.,1995; Tabira, 1997）. She died of aspiration pneumonia 
at the age of 65.  Out of 7 siblings, 4 showed the same 
disease（Watanabe et al., 1982）. 
The brain and spinal cord were ﬁxed in a 10% buffered 
neutral formalin ﬁxative for 7 days. The brain, weighing 
630g, showed severe atrophy with narrowing of gyri 
and widening of sulci in almost all lobes（Fig.1A）. 
Fig.3 a . Middle frontal gyral cortex showing many plaques of amyloid deposition
 demonstrated by an antibody against Aβ40 .    Aβ40- immunostain x 130
A. Higher magniﬁcation of  Fig.3a. Aβ40- immunostain x 260
b . The same area as Fig.3a. exhibiting innumerable plaques of amyloid deposition 
 demonstrated by an antibody against Aβ42 .    Aβ42- immunostain x 130
B. Higher magniﬁcation of  Fig.3b. Aβ42- immunostain x 260
Aβ42B
Aβ40a Aβ40A
Aβ42b
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Serial coronal sections revealed a great reduction in the 
volume of the centrum semiovale and marked dilatation 
of the lateral ventricles（Fig.1B）. The brainstem and 
cerebellum also showed considerable atrophy.  Routine 
histological examinations disclosed that there were a 
great number of NFT and SP in all cerebral cortices and 
subcortical gray matter  in addition to a great reduction 
of their neurons（Fig.2A-C, Fig.3a, A, b, B）.  Further 
findings were reported elsewhere（Yoshimura, 2005）. 
After performing routine neuropathological examinations, 
immunostained slides for phosphorylated tau（ptau）and 
Aβ, in addition to Bodian slides which were made 
extensively, were prepared and all were observed.
Results
The results of histological examinations focused on the 
occurrence of NFT and SP in the brain, spinal cord, 
peripheral nerves and ganglia, and the adrenal medulla 
are summarized in Tables 1-5.
All telencephalic neocortices had NFT of more than 
100 per gyrus and SP of more than 10 per gyrus, except 
for the calcarine cortex which had NFT of at least 126 
and SP of more than 10 per gyrus, respectively. The 
distribution of these NFT and SP in the neocortex of the 
brain is shown in Table 1. 
Almost all limbic and paralimbic cortices and nuclei 
had NFT of more than 100 and SP of more than 10. 
Although there were no SP, various numbers of NFT 
were observed in the following structures: claustrum 
91/78, caudate 8/11/8, putamen 7/8/13, globus pallidus 
6/7/5, hypothalamus 6/38, tuber cinereum 7, nucleus 
basalis of Meynert 4, diagonal band of Broca 40, 
thalamus 98/49, pulvinar 11, and mammillary body 
13.（The numbers divided by a slash indicate values 
obtained from 2-3 different parts.） The distribution of 
NFT and SP in the limbic-paralimbic system, basal 
ganglia and diencephalon is summarized in Table 2.
In the cerebral cortex, especially in the bottoms of sulci 
of frontal and temporal cortices, there were innumerable 
numbers of SP most of which were demonstrated to be 
diffuse plaques by Aβ42 immunostaining, whereas SP 
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demonstrated by Aβ40 immunostaining were mostly 
cored and much less in number at the same part of the 
cortex（Figs.3 a, A, b, and B）. 
In the brainstem, NFT were present in the substantia 
nigra 6, superior colliculus 3, inferior colliculus 7, central 
gray of midbrain and pons 5/4, locus coeruleus 3, dorsal 
tegmental nucleus 1, superior central nucleus11/12, 
reticulotegmental nucleus 5/6, pontine nuclei 9/43/22, 
nucleus of IV nerve 2, nucleus of VIII nerve 1, nucleus 
dorsalis nervi vagi l, nucleus of XII nerve 1, and inferior 
olivary nucleus 2（Table 3）.
In the cerebellum, no NFT were detectable in any 
Purkinje cells, although a few Golgi cells and one 
nucleus fastigius cell that bore NFT were observed
− 6 −
（Table 4）.  In the spinal cord, a few anterior horn 
cells bearing NFT were observed, but none were 
detectable in any ganglion cells of either posterior root 
ganglia or the Gasserian ganglion examined（Table 4）. 
Although NFT formation in adrenal medullary cells has 
been expected to occur, there is no report on the issue 
so far, except for a report on occurrence of NFT in 
pheochromocytoma cells of the adrenal medulla
（Izumiyama et al., 1990）. In the present case, 3 medullary 
cells that bore NFT were found by Bodian staining as 
well as by phosphorylated tau immunnohistochemistry. 
Two of them which were demonstrated in Bodian slides 
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had melanin granules（Fig.4 A, B）.
In the olfactory bulb（Table 5）, NFT occurred in the 
mitral cells, tufted cells and granule cells. Main 
transmitters of these cells are mitral cells（Glu/Asp, 
NAAG）, tufted cells（Glu/Asp, DA, S-P）, granule cells
（GABA, Enk）, and anterior olfactory nucleus cells
（Asp, Enk, SOM, calbindin, and parvalbumin）.
Discussion
The amyloid cascade hypothesis proposes a central role 
for Aβ amyloid in the pathogenesis of AD.  Namely, 
accumulation of Aβ in the brain is the primary 
influence driving AD pathogenesis. The rest of the 
disease process, including formation of NFT containing 
tau protein, is proposed to result from an imbalance 
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Fig. 4  A.  NFT bearing medullary cells （arrows）. Adrenal medulla  Bodian stain x 260
B.  Higher magniﬁcation of  Fig.4A. Bodian stain x 520
C.  NFT bearing medullary cells revealed by ptau immunostain   Adrenal medulla  ptau immunostain x 260
D.  Higher magniﬁcation of  Fig.4C. ptau immunostain x 520
A
C
B
D
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between Aβ production and Aβ clearance（Hardy & 
Higgins, 1992; Hardy & Selkoe, 2002）.
At a morphological level, Aβ- and tau-associated 
changes are linked so inextricably, e.g. in neuritic 
plaques, both proteins are intermingled, that it is 
difficult to assign primacy to one over the other. 
Namely, the link between Aβ generation and NFT 
formation is not known（Lowe et al, 2008）. Several 
lines of evidence point to a primary role for Aβ 
amyloid in the pathogenesis of AD. First, diffuse 
plaques are detectable in the brain of patients with 
Downʼs syndrome, before the development of neuritic 
plaques and NFT（Mann & Esiri, 1988; Lowe et al., 
2008）. Second, although mutations in the gene for tau
（MAPT）protein have not been found to be associated 
with familial AD, mutations in MAPT are associated 
with frontotemporal dementia and parkinsonism
（FTDP-17）, with extensive tau pathology in neurons 
and glia, but no amyloid deposits. Third, diverse 
neurological disorders which are different in origin are 
well known to develop NFT（tauopathies）with no 
amyloid deposits（Tolnay & Probst, 2003; Hirano & 
Tomiyasu, 2003; Lowe  et al., 2008; Murayama, 2009）.
It is also known that cognitively normal individuals can 
have a large number of neocortical plaques, although 
predominantly of diffuse type, and only sparse NFT. 
Furthermore, the correlation between plaque density 
and the severity of dementia is weak. However, the 
correlation between the severity of tau pathology（i.e. 
neuritic plaques and NFT）and the clinical severity of 
the disease is known to be best in studies that correlate 
severity of pathological features with the clinical 
severity of the disease（Lowe et al., 2008）. There are 
several key questions that remain to be solved.  First, 
what are the steps that lead from amyloid production to 
tau pathology?  Why does AD pathology occur or 
progress in some brain regions and not others?  Why 
are some neurons vulnerable to neurofibrillary tangle 
formations and others largely spared?  These questions 
are essential for understanding AD pathogenesis and 
may also be critical for therapeutic strategies（Lowe et 
al., 2008）.
  To summarize the results obtained from the present 
study, the brain in AD（Braak stage VI）with a 
PS1mutation（H163R）showed numerous Aβ42-positive 
SP together with a relative small number of Aβ40-positive 
SP in the cerebral cortices（Figs. 3 a, A, b, B）. This can 
be interpreted that Aβ42-positive SP keep increasing in 
number until the patient dies, because Aβ42 is known 
to be an initially deposited species of Aβ to form 
mature（cored）SP（Iwatsubo et al., 1994）.  
  As to NFT, neurons were classified into 3 types; 
NFT-rich, NFT-rare and NFT-free types（Table 6）.  The 
ce l l s  o f  t he  ce reb ra l  c o r t e x ,  h i p p o c a m p u s , 
parahippocampus, neostriatum and so on  belong to 
NFT-rich type. The cell of the inferior olivary nucleus, 
anterior horn of the spinal cord and adrenal medulla 
belong to the NFT-rare group and Purkinje cells and 
Gasserian ganglion cells are the only cells that belong 
to the NFT-free group（Table 6）.  Inferior olivary 
nucleus  cel ls ,  poster ior   root  gangl ion cel ls , 
paravertebral sympathetic ganglion cells, celiac 
ganglion cells and cells of the adrenal medulla have 
been known to belong to the NFT-rare group（Urasaki 
et al.,  2000; Nishimura et al.,  1993; Hirano & 
Tomiyasu, 2003; Izumiyama et al.,1990; Kawasaki et al., 
1987）.  The neuron types with easy, rare, and no NFT 
formations were summarized in Table 6 with their 
designations and main transmitters（Tohyama, 2004）. 
The neurons with easily formed NFT tend to have 
glutamate, GABA, Ach or monoamine. It may be 
necessary to clarify whether the neurons with no NFT 
formation have something to do with calcitonin gene-
related peptide.
  The present study has shown the nearly maximal 
range of NFT occurrence in the whole body. It has also 
shown that there are 3 neuron types; neuron types with 
easily formed NFT（NFT-rich）, with rarely formed 
NFT, and with no NFT formations（NFT-free）.  NFT are 
known to be mainly composed of hyperphosphorylated 
tau protein and are the hallmark of tauopathy which 
includes, other than AD, diverse neurological disorders 
of a different etiology（Tolnay & Probst,2003; Lowe et 
al., 2008）. 
In the brain, Aβ exists extracellularly and inside 
neurons. It has now become evident that in AD 
accumulation of Aβ inside neurons definitely occurs, 
largely by way of internalization by clathrin-
independent, and dynamin-dependent endocytosis
（Mohamed & de Chaves, 2011）. The soluble Aβ 
oligomers are known to be so toxic that cell death of 
neurons and glia can be induced （Chui et al., 2001; 
Ahmed et al., 2010; Fantini & Yahi, 2010; Mohamed & 
de Chaves, 2011）. The soluble oligomers develop and 
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become protofibrils, then fibrils and finally form 
neuritic plaques which contain degenerated neurites
（Ahmed et al., 2010;  Fantini& Yahi, 2010）.  
On the other hand, soluble oligomers of hyperphosphorylated 
tau, which are toxic for synapses to disintegrate, occur. 
And then they become insoluble aggregates of granular 
tau polymers inside neurons, which are so highly toxic 
that neuronal death can be induced. Finally many of 
those  aggregates of tau polymers are conjugated to 
one another to form tau fibrils, i.e., neurofibrillary 
tangles（PHF）which are believed to have no toxicity
（Santacruz et al., 2005; Maeda et al., 2007; De Felice 
et al., 2008; Takashima, 2010）.
It has become evident that hyperphosphorylation of tau 
protein is induced by activation of glycogen synthase 
kinase3β（GSK3β）which is normally inhibited by 
insulin or insulin-like growth factor（IGF）.  In AD, 
activation of GSK3β is induced by inhibition of 
insulin or IGF which is brought about by overproduced 
Aβ protein（Hong & Lee, 1997; Rankin et al., 2007）. 
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In addition, it has also become clear that both in 
familial and sporadic AD age-dependent high-density 
clustering of GM1 ganglioside at presynaptic terminals 
promotes Aβ protein fibrillogenesis（Hayashi et al., 
2004）, and such a favorable milieu is provided by 
accumulation of sphingomyelin（Hayashi et al., 2004; 
Yuyama & Yanagisawa, 2010; Fantini & Yahi, 2010）.
  However, it is still unclear why in non-Alzheimer（i.e. 
NFT only）tauopathy tau is also hyperphosphorylated 
and forms PHF, although the implication of kinases
（GSK3β and cdk5）and/or reduced activities of 
phosphatases（PP2a etc.）has been discussed so far
（Clodfelder-Miller et al., 2006; Sontag et al., 2007; 
Sontag et al., 2008; Mc Caddon & Hudson, 2010）.
  An emerging concept that was learned from 
Alzheimerʼs Aβ-peptide has been proposed（Haass & 
Selkoe, 2007）.  Namely, a series of brain proteins in 
misfolded diseases whose soluble oligomers can gain 
an adverse bioactivity  in the aggregation process and 
affect synaptic structure and plasticity,  leading to 
neural cell death（neurodegeneration）.  Although the 
mechanisms by which soluble protein oligomers kill 
neural cells are not fully understood, a common feature 
is said to be the　concentration of unstructured 
monomers on bidimensional membrane lattices. 
Membrane-bound monomers undergo a series of lipid-
dependent conformational changes, leading to the 
formation of oligomers of varying toxicity rich in β
-sheet structures or in α-helix structures（Fantini & 
Tahi, 2010）. Condensed membrane microdomains 
formed by sphingolipids and cholesterol are privileged 
sites for binding and oligomerisation of proteins. By 
controlling the balance between unstructured monomers 
and α or β conformers, shingolipids can either inhibit 
or stimulate the oligomerisation of proteins（Fantini & 
Tahi , 2010; Matsuzaki et al., 2010）.
  Molecular analyses that reveal all of qualitative and 
quantitative differences between NFT-rich and NFT-
free neuron types, e.g. by using laser microdissection and 
proteome, transmitters and phospholipids（especially 
sphingolipids）analyses, may be a way to obtain some 
clue to the pathogenesis of NFT formation.  The 
clarification of NFT pathogenesis will surely open a 
road to preventions and inhibitions of not only AD but 
also many of other tauopathies. 
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アルツハイマー病の固有病変（神経原線塊と老人斑）の発現範囲 ―38歳で発症し
25年の経過をとった家族性アルツハイマー病例の病理・解剖学的研究―
吉　村　教　暤１）
１）弘前医療福祉大学保健学部医療技術学科 病態神経科学・病理学
　　〒 036-8102 弘前市小比内 3-18-1
要　　　旨
アルツハイマー病（AD）は近年急増しつつある認知症で、その医療・福祉対策は大きな社会問題であり、
根治療法の開発がまたれる。AD の脳病変は3つの組織細胞病変−神経原線維塊、Aβ沈着（老人斑）、
細胞脱落−で特徴づけられる。本研究では 25 年経過の AD 剖検例検索を契機にその固有病変の発現範
囲を明らかにした。その結果 NFT が形成されやすいニューロン群と稀にしか形成されない群と 全く形
成されない群に分類された。 AD の脳病変形成については、Aβカスケード仮説によれば、まず最初に
Aβの沈着がおこり、その際 Aβのオリゴマーが最も細胞毒性があり、プロトフィブリル、フィブリル
へと発展してやがて neuritic plaque となる。また、神経細胞内やシナプス部に Aβオリゴマーが生じて
神経細胞やグリア細胞に毒性に作用して細胞死を誘導すると考えられている。他方、神経細胞内では
Aβの産生過剰により GSK3βが賦活されるなどにより、タウの過剰リン酸化が進み可溶性オリゴマー
が重合して不溶性のタウ顆粒状凝集体となり、さらに大きな不溶性の神経原線維塊になると考えられて
いる。しかし、Aβオリゴマーやプロトフィブリルと、タウオリゴマーや顆粒状凝集体がどこで会合し
て互いを発達させるのか、また NFT のみのタウオパシーのタウリン酸化機序等も十分には明らかでは
ない。NFT が形成されやすい細胞群とされない細胞群の相違の詳細な検討から、NFT 形成機序に通じ
る手掛かりが得られる可能性がある。
キーワード：アルツハイマー病、神経原線維塊、老人斑、タウ蛋白質、アミロイドβ （Aβ）
